Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stephen Haggarty
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rodin Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Haggarty has equity in the private company Rodin Therapeutics and receives income from the company for consulting services. Rodin Therapeutics’ core focus is HDAC inhibitors, tailored for the long-term therapy of brain diseases. Rodin Therapeutics discovers and develops therapeutics for neurological disorders by investigating the role of HDAC inhibition in the cognitive dysfunction associated with Parkinson’s disease and is working to discover and develop epigenetic modulators of synaptic resilience for the treatment of cognitive and functional impairment due to Alzheimer’s disease. The research focuses on the relationships between HDAC6 and certain neurological diseases, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, with the goal of driving therapeutic development for neurological disease. The overall aim of the research is to develop a positron emission tomography (PET) radiotracer to quantify HDAC6 density in the human brain as a function of normal aging and natural human variability for comparison to disease states and for assessing in vivo HDAC6 target engagement. Because the research aims to produce a key tool for HDAC drug development for neurological diseases and the company aims to develop therapeutics for neurological disorders using HDAC inhibitors, the results of this study could be of interest to the company.
Epigenetic Radiotracers for PET Imaging: Isoform-SelectiveHDAC Probes
Project Narrative Although homologous to other histone deacetylases (HDACs), the isoform named HDAC6 regulates the acetylation state of distinct non-histone proteins and when chemically inhibited has shown efficacy in animal models of mood disorders, neurodegenerative diseases and certain cancers. Currently, there are no tools for determining HDAC6 density and dysregulation in the living human brain. The development of an HDAC6 radiotracer for use in positron emission tomography will provide quantitative maps of HDAC6 in the human brain and will accelerate the development of therapies based on HDAC6 inhibition.
Filed on July 06, 2017.
Tell us what you know about Stephen Haggarty's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Stephen Haggarty filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Stephen Haggarty | Massachusetts General Hospital | Conflict of Interest | Rodin Therapeutics | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.